Free Trial
LON:ORPH

Open Orphan (ORPH) Share Price, News & Analysis

Open Orphan logo

About Open Orphan Stock (LON:ORPH)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
10
10
52-Week Range
N/A
Volume
652,639 shs
Average Volume
1.56 million shs
Market Capitalization
£67.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Open Orphan Plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company is headquartered in London, the United Kingdom.

Receive ORPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Open Orphan and its competitors with MarketBeat's FREE daily newsletter.

ORPH Stock News Headlines

Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.
Open Orphan PLC (CRO.BE)
See More Headlines

ORPH Stock Analysis - Frequently Asked Questions

Shares of ORPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Open Orphan investors own include HSBC (HSBA), Royal Dutch Shell (RDSB), Cassava Sciences (SAVA), Barclays (BARC), EQTEC (EQT), Grafton Group (GFTU) and Lloyds Banking Group (LLOY).

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
LON:ORPH
CIK
N/A
Fax
N/A
Employees
179
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£34.71 million
Price / Cash Flow
4.17
Book Value
GBX 3.10 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
£67.09 million
Optionable
Not Optionable
Beta
N/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (LON:ORPH) was last updated on 5/18/2025 by MarketBeat.com Staff
From Our Partners